The role of mucosal serotonin in visceral nociception and gut motility
The role of mucosal serotonin in visceral nociception and gut motility
批准号:
10535862
负责人:
Sarah Najjar
金额:
$6.76万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-07 至 2025-09-06
关键词:
Abdominal PainAblationAdultAdverse effectsAfferent NeuronsAnabolismBiological AssayCell secretionChemicalsChildChildhoodColonCommunicationConstipationCre driverDataDiarrheaDiseaseEnteralEnteric Nervous SystemEnterochromaffin CellsEnzymesEpithelialEpithelial CellsFunctional disorderGastrointestinal MotilityGastrointestinal TransitGastrointestinal tract structureInterventionIrritable Bowel SyndromeLeadLocationMeasurementMediatingMigrating Myoelectric ComplexMorbidity - disease rateMotorMucous MembraneMusNerveNeuraxisNeuronsNociceptionPainPersonsPharmacologyPhysiologicalPlayReflex actionRegulationResearchRoleSelective Serotonin Reuptake InhibitorSensorySerotoninSignal TransductionSiteSpinalSymptomsTechniquesTestingTransgenic MiceTryptophan 5-monooxygenaseVisceralVisceral painbehavior measurementcell motilitycolorectal distensioncosteffective therapyexperimental studygastrointestinalgastrointestinal epitheliumimprovedin vivointervention effectintestinal epitheliummechanical stimulusmotility disordernoveloptogeneticsparacrineresponsereuptakesensorserotonin receptorspatiotemporaltool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Irritable bowel syndrome (IBS) is a highly prevalent disorder characterized by visceral pain and dysmotility.
IBS causes substantial morbidity in children and adults and current therapy is inadequate. Serotonin (5-HT)
signaling plays roles in pain and motility, but the efficacy of modifying 5-HT signaling to treat IBS is limited and
fraught with adverse effects. A greater understanding of how enteric 5-HT contributes to IBS pathophysiology
may therefore provide for novel and effective treatments for the condition. Enterochromaffin (EC) cells in the
gastrointestinal (GI) epithelium produce most of the 5-HT in the gut, which is thought to stimulate extrinsic primary
afferent neuron (ExPAN) and intrinsic primary afferent neuron (IPAN) terminals to promote sensory and motor
signaling, respectively. The serotonin reuptake transporter (SERT), present throughout epithelial cells, rapidly
inactivates 5-HT. Selective serotonin reuptake inhibitors (SSRIs) inhibit SERT and thus increase 5-HT availability
for IPAN and ExPAN stimulation. Despite their use for pediatric IBS, SSRIs are often ineffective and plagued by
adverse GI effects, which may be due to their effects at sites other than the GI epithelium. My prior and
preliminary data strongly suggest that epithelial-restricted 5-HT modulation may limit unwanted effects and thus
improve therapy. My data also show a novel visceral pain mechanism involving SERT regulation of mucosal 5-
HT. In the current proposal, I will investigate the effects of epithelial 5-HT on GI motility and visceral nociception
using optogenetic tools that induce or inhibit EC cell secretion, mouse lines that either lack mucosal 5-HT or
SERT, and pharmacological interventions that alter mucosal 5-HT signaling. The proposed research strategy
will allow me to test the hypotheses that 1) 5-HT released from EC cells and 2) SERT-mediated regulation of
mucosal 5-HT availability modulate visceral nociception and GI motility.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of mucosal serotonin in visceral nociception and gut motility
-
批准号:10710171
-
项目类别:
-
资助金额:$7.18万
-
财政年份:2022
-
负责人:Sarah Najjar
-
依托单位:
海外基金